Halozyme Therapeutics Inc

22 de out. de 2026, 20:07 UTC

Halozyme Therapeutics Inc shares are declining, pulling back from earlier gains, though remaining above the 20-day moving average after closing higher in recent sessions.

21 de out. de 2026, 20:07 UTC

Halozyme Therapeutics Inc is advancing amid broader market gains, maintaining an upward trajectory despite earlier pulling back from a session high.

20 de out. de 2026, 19:16 UTC

Halozyme Therapeutics Inc is trading higher, gaining since Monday's close and remaining well above its 20-day moving average.

19 de out. de 2026, 23:01 UTC

Halozyme Therapeutics Inc shares advanced in after-market trading, reaching a peak shortly after the regular session ended, continuing a trend of five consecutive higher daily closes.

15 de out. de 2026, 20:02 UTC

Halozyme Therapeutics Inc shares are advancing sharply, reaching their highest cumulative return since Wednesday's close amid notable trading activity.

14 de out. de 2026, 23:52 UTC

Halozyme Therapeutics Inc is trading higher in after-market hours, continuing an upward trend since Wednesday's close and remaining above its 20-day moving average.

13 de out. de 2026, 20:08 UTC

TD Cowen analyst Brendan Smith raised Halozyme Therapeutics' price target to $130.00 from $105.00 while maintaining a Buy rating.

12 de out. de 2026, 20:06 UTC

Halozyme Therapeutics Inc shares are trading modestly higher, fluctuating around the midpoint of their one-month range, with a peak observed in the late morning.

9 de out. de 2026, 20:12 UTC

Halozyme Therapeutics Inc shares advanced modestly in after-market trading, remaining around the midpoint of their one-month range following Friday's close.

8 de out. de 2026, 20:07 UTC

Halozyme Therapeutics received price target increases from JPMorgan to $78 and HC Wainwright to $130, while winning a patent case against Merck in the Netherlands.

7 de out. de 2026, 20:07 UTC

Halozyme Therapeutics shares advanced after a Dutch court ruling found Merck infringed on its MDASE patent, halting Keytruda SC sales in several European countries.

6 de out. de 2026, 19:45 UTC

Halozyme Therapeutics Inc is trading higher, with its cumulative return peaking earlier in the day while settling at a lower level within its one-month trading range.

2 de out. de 2026, 20:07 UTC

Halozyme Therapeutics Inc is advancing, continuing a higher trend since Thursday's close amid a broader market increase, contrasting with the previous five sessions.

1 de out. de 2026, 20:02 UTC

Halozyme Therapeutics Inc shares fell sharply, diverging from a recent trend of higher daily closes amid unusually high trading volume.

29 de set. de 2026, 20:07 UTC

Halozyme Therapeutics Inc shares fell sharply, marking a fourth consecutive lower daily close, despite remaining above its 20-day moving average.

25 de set. de 2026, 19:55 UTC

Halozyme Therapeutics Inc shares fell, despite a strong performance backdrop, remaining above the 20-day moving average and near the upper end of its one-month trading range.

24 de set. de 2026, 23:11 UTC

Halozyme Therapeutics Inc is trading modestly higher in after-market hours, remaining above its 20-day moving average and near the upper end of its one-month range.

23 de set. de 2026, 20:07 UTC

Halozyme Therapeutics Inc shares fell sharply after reaching a 52-week high, facing volatility and a decline during Wednesday's trading session.

22 de set. de 2026, 20:02 UTC

Halozyme Therapeutics Inc shares are rising as the company announced a $1.05 billion offering of convertible senior notes to enhance financial flexibility.

21 de set. de 2026, 20:06 UTC

Halozyme Therapeutics Inc shares fell as the company announced a proposed offering of $1.05 billion in convertible senior notes to extend debt maturity.

18 de set. de 2026, 20:06 UTC

Halozyme Therapeutics priced an upsized $1.3 billion offering of convertible senior notes, with shares trading higher amid strong session momentum.

17 de set. de 2026, 20:07 UTC

Halozyme Therapeutics announced a $1.05 billion convertible senior notes offering due in 2033, with shares trading higher amid strong performance metrics.

16 de set. de 2026, 23:01 UTC

Halozyme Therapeutics announced a proposed $1.05 billion offering of convertible senior notes, contributing to a decline in after-market trading.

15 de set. de 2026, 22:06 UTC

Halozyme Therapeutics Inc. shares were near unchanged in after-market hours, trading within a narrow range and below their 20-day moving average.

9 de set. de 2026, 20:07 UTC

Halozyme Therapeutics Inc is declining during Wednesday's session, continuing a trend lower since Tuesday. The stock remains above its 20-day moving average.

8 de set. de 2026, 19:26 UTC

Halozyme Therapeutics is trading lower, reflecting weakness after reaching a session high earlier. The stock remains down since Friday's close.

2 de set. de 2026, 20:08 UTC

HC Wainwright reiterated its Buy rating on Halozyme Therapeutics, maintaining a $115 price target as shares trade higher amid upcoming investor conference participation.

1 de set. de 2026, 20:08 UTC

Halozyme Therapeutics is rising today, driven by broader strength in biotechnology stocks. The stock remains near the upper end of its one-month range.

28 de ago. de 2026, 20:08 UTC

Halozyme Therapeutics Inc shares declined Friday, reversing earlier gains amid rising U.S. Treasury yields and inflation concerns, with no specific news identified.

27 de ago. de 2026, 19:16 UTC

Shares of Halozyme Therapeutics are lower during Thursday's session, reaching a low earlier. The stock remains above its 20-day moving average.